Connecticut
+ (203) 597-9100

Clinical Studies at The Eye Care Group: Opportunities to Further Science

Many physicians at The Eye Care Group are involved in clinical studies investigating treatment and prevention of important eye conditions. We invite you to participate in these clinical studies to further the field of ophthalmic knowledge and receive the potential benefits of cutting edge research. Please email our clinical studies coordinator, Sue Heaton studies@theeyecaregroup.com for more information.

Cornea

The Dry Eye Study, Phase III

Investigators: Dr. Geffin

Description: Dr. Geffin continues to recruit participants for the Mobile Dry Eye Lab where he is involved in a multi-center study of promising new therapies for dry eye.

 

Neuro-ophthalmology

A Non-Treatment Study of Risk Factors for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigators: Dr. Lesser and Dr. Kostina-O’Neil

Description: This Pfizer study is recruiting male volunteers age 45 or older that have experienced a sudden, recent vision decrease due to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) in order to study any correlation between this condition and medications.

 

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet plus Acetazolamide vs Diet plus Placebo in Subjects with Idiopathic Intracranial Hypertension (IIH) with Mild Visual Loss

Investigators: Dr. Lesser and Dr. Kostina-O’Neil

Description: Description: This study is recruiting 18-60 year-old females with Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri, to determine if diet alone will effectively treat IIH, or if medications are needed as well.

 

OMG: Ocular Myasthenia Gravis

Investigators: Dr. Lesser

Description: Description: To conduct a pilot study to identify potential serum biomarkers (DNA polymorphisms, circulating microRNA, white blood cell mRNA, nanoparticle proteomics) and link these with clinical phenotypes in a cohort of ocular myasthenia gravis (OMG) patients with precisely defined clinical characteristics. Biomarkers identified will be utilized in later clinical trial settings in OMG and MG.

 

Pediatric Ophthalmology

Intermittent Exotropia (IXT1)

Investigators: Dr. Levada and Dr. Cronin

Description: For children with intermittent exotropia, or an outward eye turn, requiring surgical intervention, we are currently enrolling patients ages 3 years to less than 11 years of age in a study comparing the results of two equally adopted approaches: surgery on two muscles of one eye compared to surgery on one muscle of each eye.

 

Intermittent Exotropia (IXT2)

Investigators: Investigators: Dr. Levada and Dr. Cronin

Description: This study compares observation to eye patching for treatment of intermittent exotropia, or outward eye turn, in children ages 12 months to less than 11 years of age.

 

Amblyopia Treatment Study 15 (ATS15)

Investigators: Dr. Levada and Dr. Cronin

Description: Description: Children ages 3 years to less than 8 years old who have failed traditional amblyopia therapy of either part-time eye patching or Atropine penalization may enroll in this study to investigate the efficacy of increasing the duration of eye patching to an average of 6 hours daily.

 

Amblyopia Treatment Study 16 (ATS16)

Investigators: Dr. Levada and Dr. Cronin

Description: Children ages 3 years to less than 8 years old, who have failed traditional amblyopia therapy of either part-time eye patching or Atropine penalization may enroll in this study to investigate the efficacy of removing the corrective lens in front of the stronger, atropinized eye to augment amblyopia treatment.

 

Amblyopia Treatment Study 17 (ATS17)

Investigators: Dr. Levada and Dr. Cronin

Description: Children ages 7 to have failed traditional amblyopia therapy of either part-time eye patching or Atropine penalization may enroll in this study to compare the efficacy and safety of adding an oral medication, levodopa, to patching. Levodopa has a good safety profile in the pediatric population and has shown promise in the treatment of residual amblyopia.